These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Disease-free survival following high dose or standard dose therapy in patients with amyloidosis. Kiel PJ; Trueg AO; Ferguson M; Benson M; Abonour R Br J Haematol; 2016 Jul; 174(1):153-5. PubMed ID: 26314806 [No Abstract] [Full Text] [Related]
10. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076 [No Abstract] [Full Text] [Related]
11. Clinical Characteristics and Treatment Outcome of Chinese Patients With Systemic Amyloid Light-Chain Amyloidosis: A Retrospective Single-Center Analysis. Zhao Q; Li F; Song P; Zhou X; Wang L; Yu Y; An Z; Wang X; Zhai Y Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):104-10. PubMed ID: 26752455 [TBL] [Abstract][Full Text] [Related]
12. Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis. Devine SM Biol Blood Marrow Transplant; 2014 Jan; 20(1):14-9. PubMed ID: 24291621 [No Abstract] [Full Text] [Related]
13. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report. Chen W; Ren G; Zuo K; Huang X Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027 [TBL] [Abstract][Full Text] [Related]
14. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
15. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060 [TBL] [Abstract][Full Text] [Related]